Condition
Neurodegenerative Disease, Hereditary
Total Trials
5
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 3 (1)
Trial Status
Completed2
Recruiting2
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06672237Phase 3Recruiting
A Phase 3 Study of NTLA-2001 in ATTRv-PN
NCT05518617Recruiting
Molecular and Functional Imaging in Monogenic PD.
NCT06177028Phase 2Not Yet Recruiting
MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment
NCT04580979CompletedPrimary
Natural History Study of FDXR Mutation-related Mitochondriopathy
NCT04594590CompletedPrimary
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy
Showing all 5 trials